

# Daniel J Deangelo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1372479/publications.pdf>

Version: 2024-02-01

232  
papers

17,832  
citations

25034

57  
h-index

14208

128  
g-index

235  
all docs

235  
docs citations

235  
times ranked

17534  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Tyrosine Kinase Created by Fusion of the <i>PDGFRA</i> and <i>FIP1L1</i> Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. <i>New England Journal of Medicine</i> , 2003, 348, 1201-1214.	27.0	1,655
2	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017, 130, 722-731.	1.4	1,173
3	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 740-753.	27.0	1,047
4	Differentiation and reversal of malignant changes in colon cancer through PPAR $\beta$ . <i>Nature Medicine</i> , 1998, 4, 1046-1052.	30.7	933
5	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2349.	7.4	758
6	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. <i>Blood</i> , 2015, 125, 1367-1376.	1.4	747
7	Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. <i>Blood</i> , 2005, 105, 54-60.	1.4	632
8	Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy. <i>Science</i> , 2011, 334, 1129-1133.	12.6	502
9	Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3. <i>Journal of Clinical Oncology</i> , 2010, 28, 4339-4345.	1.6	442
10	Ponatinib efficacy and safety in Philadelphia chromosome <sup>+</sup> positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	1.4	392
11	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet</i> , The, 2021, 398, 491-502.	13.7	315
12	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2003, 102, 1578-1582.	1.4	299
13	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	299
14	Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML. <i>Cell</i> , 2012, 151, 344-355.	28.9	294
15	Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. <i>Blood</i> , 2007, 109, 5136-5142.	1.4	287
16	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , 2019, 381, 2315-2326.	27.0	257
17	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
18	The frequency and management of asparaginase <sup>-</sup> related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. <i>British Journal of Haematology</i> , 2011, 152, 452-459.	2.5	216

#	ARTICLE	IF	CITATIONS
19	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. <i>Cancer</i> , 2019, 125, 2474-2487.	4.1	210
20	AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. <i>Blood</i> , 2014, 123, 905-913.	1.4	205
21	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014, 4, 1074-1087.	9.4	201
22	Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. <i>Leukemia and Lymphoma</i> , 2011, 52, 2237-2253.	1.3	198
23	Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. <i>Blood</i> , 2006, 108, 3477-3483.	1.4	194
24	Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. <i>Journal of Clinical Oncology</i> , 2007, 25, 813-819.	1.6	171
25	Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project. <i>Leukemia Research</i> , 2007, 31, 599-604.	0.8	164
26	Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2016, 175, 496-504.	2.5	162
27	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. <i>Lancet Haematology</i> , 2017, 4, e387-e398.	4.6	158
28	A precision therapy against cancers driven by KIT/PDGFRA mutations. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	157
29	Chronic Myelogenous Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 984-1023.	4.9	151
30	Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1385-1415.	4.9	147
31	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. <i>Blood</i> , 2018, 131, 387-396.	1.4	131
32	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. <i>Cell Stem Cell</i> , 2021, 28, 514-523.e9.	11.1	130
33	SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 226-242.	16.8	126
34	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	1.4	122
35	Targeting MTHFD2 in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016, 213, 1285-1306.	8.5	118
36	Acute Lymphoblastic Leukemia, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1240-1279.	4.9	116

#	ARTICLE	IF	CITATIONS
37	Health care utilization and end-of-life care for older patients with acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2840-2848.	4.1	113
38	Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 725.	7.1	111
39	Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. <i>Cancer</i> , 2013, 119, 90-98.	4.1	104
40	Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. <i>Blood Advances</i> , 2017, 1, 1167-1180.	5.2	103
41	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. <i>American Journal of Hematology</i> , 2018, 93, 1301-1310.	4.1	98
42	The intersection of genetic and chemical genomic screens identifies GSK-3 $\beta$ as a target in human acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2012, 122, 935-947.	8.2	96
43	Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 29-41.	16.8	95
44	Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 877-882.	1.7	95
45	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	1.4	90
46	The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 301-313.	30.7	79
47	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. <i>Nature Medicine</i> , 2021, 27, 2192-2199.	30.7	79
48	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. <i>Nature Medicine</i> , 2021, 27, 2183-2191.	30.7	78
49	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
50	Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation. <i>Clinical Cancer Research</i> , 2004, 10, 5065-5071.	7.0	72
51	Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. <i>American Journal of Hematology</i> , 2016, 91, 322-329.	4.1	72
52	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , 2018, 118, 1425-1433.	6.4	72
53	Exploiting an Asp-Glu switch in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	69
54	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1091-1102.	4.9	67

#	ARTICLE	IF	CITATIONS
55	New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 3504-3519.	1.6	67
56	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. <i>Blood</i> , 2018, 131, 2816-2825.	1.4	64
57	Phase III trial of panobinostat, an oral histone deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis. <i>British Journal of Haematology</i> , 2013, 162, 326-335.	2.5	61
58	A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. <i>Blood</i> , 2018, 132, 1125-1133.	1.4	60
59	NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1505-1512.	4.9	57
60	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. <i>Blood Advances</i> , 2017, 1, 331-340.	5.2	57
61	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. <i>Blood</i> , 2015, 126, 323-323.	1.4	57
62	Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 247-254.	3.7	55
63	Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. <i>Blood</i> , 2019, 134, 867-879.	1.4	55
64	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1720-1729.	2.0	53
65	Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. <i>Blood</i> , 2009, 114, 4027-4033.	1.4	52
66	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. <i>Journal of Hematology and Oncology</i> , 2018, 11, 143.	17.0	52
67	The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 123-130.	2.5	50
68	The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling. <i>Molecular and Cellular Biology</i> , 2014, 34, 2517-2532.	2.3	48
69	Neutrophil Fcγ3RIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. <i>Journal of Clinical Investigation</i> , 2017, 127, 3810-3826.	8.2	48
70	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the ß3-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000539.	1.2	47
71	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia. <i>Blood</i> , 2007, 110, 587-587.	1.4	47
72	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. <i>Leukemia</i> , 2019, 33, 2393-2402.	7.2	44

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. <i>Cancer</i> , 2018, 124, 1722-1732.	4.1	43
74	A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). <i>Blood Advances</i> , 2020, 4, 1683-1689.	5.2	43
75	A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma. <i>Blood</i> , 2015, 126, 1328-1328.	1.4	43
76	Recent Advances in Managing Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 330-342.	3.8	40
77	Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2016, 126, 3827-3836.	8.2	40
78	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1135-1146.	1.4	39
79	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. <i>Blood</i> , 2015, 126, 80-80.	1.4	38
80	Nelarabine for the Treatment of Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1121-1135.	2.2	35
81	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. <i>Blood</i> , 2021, 137, 2463-2480.	1.4	35
82	Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. <i>Blood Cancer Journal</i> , 2020, 10, 81.	6.2	34
83	The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial. <i>Blood</i> , 2014, 124, 968-968.	1.4	34
84	KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial. <i>Blood</i> , 2010, 116, 316-316.	1.4	33
85	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. <i>Journal of Hematology and Oncology</i> , 2022, 15, 1.	17.0	33
86	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.8	32
87	Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.. <i>Blood</i> , 2008, 112, 958-958.	1.4	32
88	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 870-881.	7.0	32
89	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. <i>Modern Pathology</i> , 2015, 28, 965-976.	5.5	31
90	The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 306-314.	2.1	31

#	ARTICLE	IF	CITATIONS
91	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosomeâ€“positive relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 905-913.	4.1	30
92	Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. <i>Journal of Geriatric Oncology</i> , 2015, 6, 288-298.	1.0	29
93	Treatment of young adults with Philadelphiaâ€“negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyperâ€“CVAD vs. pediatricâ€“inspired regimens. <i>American Journal of Hematology</i> , 2018, 93, 1254-1266.	4.1	29
94	Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	29
95	SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. <i>Blood</i> , 2015, 126, 454-454.	1.4	29
96	RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. <i>Cell Reports</i> , 2015, 13, 2345-2352.	6.4	28
97	The clinical and functional effects of <i>TERT</i> variants in myelodysplastic syndrome. <i>Blood</i> , 2021, 138, 898-911.	1.4	27
98	Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). <i>Leukemia Research</i> , 2013, 37, 1016-1020.	0.8	26
99	The prevention and management of asparaginaseâ€“related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 278-284.	3.8	26
100	A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 324-324.	1.4	26
101	Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. <i>Blood Advances</i> , 2021, 5, 5536-5545.	5.2	24
102	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 430-434.	0.8	23
103	Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 2379-2388.	4.1	23
104	Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2209-2209.	1.4	22
105	ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. <i>Blood</i> , 2015, 126, 138-138.	1.4	22
106	Insulin receptor substrate 1 is a substrate of the Pim protein kinases. <i>Oncotarget</i> , 2016, 7, 20152-20165.	1.8	22
107	Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. <i>Leukemia</i> , 2022, 36, 2108-2120.	7.2	22
108	Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. <i>Blood Advances</i> , 2022, 6, 5750-5762.	5.2	20



#	ARTICLE	IF	CITATIONS
109	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. <i>Lancet Haematology</i> , 2016, 3, e276-e283.	4.6	19
110	A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected. <i>Oncology and Therapy</i> , 2018, 6, 9-20.	2.6	19
111	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e122-e133.	4.6	19
112	Current challenges and opportunities in treating adult patients with Philadelphia $\phi$ -negative acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 705-723.	2.5	18
113	A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage. <i>Blood</i> , 2014, 124, 2255-2255.	1.4	18
114	Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 747-751.	0.8	16
115	The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 400-405.	2.5	16
116	Self-reported sleep disturbance and survival in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2017, 177, 562-566.	2.5	16
117	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 85, 106197.	0.8	16
118	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. <i>Clinical Cancer Research</i> , 2021, 27, 2742-2754.	7.0	16
119	Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study. <i>Blood</i> , 2021, 138, 318-318.	1.4	16
120	Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 370-379.	2.3	15
121	Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). <i>Blood</i> , 2018, 132, 351-351.	1.4	15
122	Prospective Cohort Study of Geriatric Assessment in Older Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 4285-4285.	1.4	15
123	Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia $\phi$ -negative acute lymphoblastic leukemia in first remission. <i>American Journal of Hematology</i> , 2016, 91, 793-799.	4.1	14
124	Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2017, 10, 1033-1045.	2.2	14
125	Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. <i>Blood Advances</i> , 2021, 5, 4352-4360.	5.2	14
126	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. <i>Blood</i> , 2012, 120, 230-230.	1.4	14



#	ARTICLE	IF	CITATIONS
127	Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. <i>Leukemia and Lymphoma</i> , 2010, 51, 363-375.	1.3	13
128	Myeloid neoplasm demonstrating a <i>STAT5B-RARA</i> rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000307.	1.2	13
129	Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 204-210.	0.8	13
130	Epidemiologic Investigation of a Cluster of Neuroinvasive <i>Bacillus cereus</i> Infections in 5 Patients With Acute Myelogenous Leukemia. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv096.	0.9	13
131	Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1786-1789.	5.2	13
132	Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to reinduction chemotherapy. <i>American Journal of Hematology</i> , 2020, 95, 245-250.	4.1	13
133	Safety and Efficacy from a Phase 1b/2 Study of IMG632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 372-372.	1.4	13
134	Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. <i>Leukemia and Lymphoma</i> , 2022, 63, 1934-1941.	1.3	13
135	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 254-261.	4.1	12
136	Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc concentration modelling. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 590-600.	2.4	12
137	Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. <i>Modern Pathology</i> , 2020, 33, 1135-1145.	5.5	12
138	Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML). <i>Blood</i> , 2006, 108, 158-158.	1.4	12
139	A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. <i>Blood</i> , 2013, 122, 1437-1437.	1.4	12
140	Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM). <i>Blood</i> , 2016, 128, 477-477.	1.4	12
141	A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults. <i>Blood</i> , 2021, 138, 2305-2305.	1.4	12
142	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. <i>American Journal of Hematology</i> , 2019, 94, 408-416.	4.1	11
143	Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. <i>Histopathology</i> , 2017, 71, 112-124.	2.9	10
144	Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. <i>Cancer</i> , 2019, 125, 3845-3852.	4.1	10

#	ARTICLE	IF	CITATIONS
145	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.	1.3	10
146	Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study. <i>Blood</i> , 2020, 136, 37-38.	1.4	10
147	Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 40-41.	1.4	10
148	Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. <i>Experimental Hematology</i> , 2022, 107, 14-19.	0.4	10
149	Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. <i>Journal of Clinical Pathology</i> , 2018, 71, 653-658.	2.0	9
150	Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 3906-3906.	1.4	9
151	GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study. <i>Blood</i> , 2017, 130, 894-894.	1.4	9
152	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. <i>Journal of Clinical Oncology</i> , 2022, 40, 3709-3718.	1.6	9
153	Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e302-e312.	3.8	8
154	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq0.0 rgBT\$Overlock 1	1.4	8
155	Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. <i>Blood Advances</i> , 2022, 6, 2835-2846.	5.2	8
156	Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 3908-3908.	1.4	7
157	Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.. <i>Blood</i> , 2009, 114, 2898-2898.	1.4	7
158	The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study. <i>Blood</i> , 2010, 116, 658-658.	1.4	7
159	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. <i>Blood</i> , 2015, 126, 2861-2861.	1.4	7
160	Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. <i>Blood</i> , 2015, 126, 4025-4025.	1.4	7
161	Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. <i>Blood Advances</i> , 2022, 6, 72-81.	5.2	7
162	Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1053-7.	2.3	6

#	ARTICLE	IF	CITATIONS
163	Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 245-251.	0.4	6
164	How to treat chronic myeloid leukemia (CML) in older adults. <i>Journal of Geriatric Oncology</i> , 2018, 9, 291-295.	1.0	6
165	Single 6-mg dose of rasburicase: The experience in a large academic medical center. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1349-1356.	0.9	6
166	Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis. <i>Blood</i> , 2020, 136, 41-42.	1.4	6
167	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. <i>Blood</i> , 2012, 120, 3747-3747.	1.4	6
168	Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 3-12.	2.5	5
169	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. <i>Leukemia</i> , 2021, 35, 1166-1175.	7.2	5
170	Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. <i>Haematologica</i> , 2021, 106, 1787-1793.	3.5	5
171	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. <i>Blood Advances</i> , 2022, 6, 818-827.	5.2	5
172	Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial. <i>Blood</i> , 2012, 120, 3763-3763.	1.4	5
173	DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions. <i>Blood</i> , 2015, 126, 2549-2549.	1.4	5
174	Tailored Approaches to Induction Therapy for Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 583-586.	1.6	4
175	Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation. <i>Journal of Clinical Pathology</i> , 2019, 72, 93-96.	2.0	4
176	Tâ€œcell acute lymphoblastic leukemia: Current approach and future directions. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e70.	0.9	4
177	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2006, 108, 1858-1858.	1.4	4
178	MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. <i>Blood</i> , 2013, 122, 1443-1443.	1.4	4
179	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). <i>Blood</i> , 2013, 122, 1496-1496.	1.4	4
180	Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S44-S47.	0.4	3

#	ARTICLE	IF	CITATIONS
181	Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. <i>British Journal of Haematology</i> , 2020, 191, e77-e81.	2.5	3
182	Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Clinical and Translational Science</i> , 2021, 14, 184-193.	3.1	3
183	Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors. <i>Blood</i> , 2013, 122, 3749-3749.	1.4	3
184	Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration. <i>Leukemia Research Reports</i> , 2019, 12, 100189.	0.4	2
185	Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. <i>Blood</i> , 2019, 134, 2950-2950.	1.4	2
186	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	1.4	2
187	Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. <i>Blood</i> , 2012, 120, 3749-3749.	1.4	2
188	BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia. <i>Blood</i> , 2013, 122, 238-238.	1.4	2
189	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. <i>Blood</i> , 2004, 104, 300-300.	1.4	2
190	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2009, 114, 587-587.	1.4	2
191	Targeting MTHFD2 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 443-443.	1.4	2
192	Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study. <i>Blood</i> , 2021, 138, 2565-2565.	1.4	2
193	Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic. <i>Blood</i> , 2021, 138, 2291-2291.	1.4	2
194	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMG632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4440-4440.	1.4	2
195	Pretreatment clinical and genetic factors predict early post-treatment mortality in fit <sc>AML</sc> patients following induction. <i>American Journal of Hematology</i> , 2021, 96, E259-E262.	4.1	1
196	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. <i>Blood</i> , 2006, 108, 259-259.	1.4	1
197	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. <i>Blood</i> , 2008, 112, 1011-1011.	1.4	1
198	The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols.. <i>Blood</i> , 2009, 114, 3073-3073.	1.4	1

#	ARTICLE	IF	CITATIONS
199	QoL of pediatric-inspired compared to hyper-CVAD regimens for newly diagnosed AYA patients with Ph-ALL: A modeling analysis.. Journal of Clinical Oncology, 2017, 35, e22002-e22002.	1.6	1
200	Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study. Blood, 2021, 138, 4406-4406.	1.4	1
201	A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2021, 138, 4429-4429.	1.4	1
202	Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. British Journal of Haematology, 2022, 198, 421-430.	2.5	1
203	Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e836-e843.	0.4	1
204	Preface. Hematology/Oncology Clinics of North America, 2011, 25, ix-x.	2.2	0
205	Colonic Wall Thickening as the First Indicator of Relapse of Acute Lymphoblastic Leukemia. ACG Case Reports Journal, 2019, 6, e00207.	0.4	0
206	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	1.4	0
207	Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.. Blood, 2005, 106, 2788-2788.	1.4	0
208	A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without Cloretazine® in Patients with First Relapse of Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 1970-1970.	1.4	0
209	JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations.. Blood, 2007, 110, 1634-1634.	1.4	0
210	Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3 $\beta$ (GSK-3 $\beta$ ) as a Modulator of Differentiation In Acute Myeloid Leukemia. Blood, 2010, 116, 1000-1000.	1.4	0
211	Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients. Blood, 2011, 118, 239-239.	1.4	0
212	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. Blood, 2011, 118, 1442-1442.	1.4	0
213	Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.. Blood, 2012, 120, 2792-2792.	1.4	0
214	Geriatric Assessment Variables Add Prognostic Value to the International Prognostic Scoring System. Blood, 2012, 120, 4933-4933.	1.4	0
215	Flow Cytometric Evaluation Of Minimal Residual Disease In Adult Acute Lymphoblastic Leukemia Using a Simplified, Single-Tube Approach. Blood, 2013, 122, 1378-1378.	1.4	0
216	HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. Blood, 2013, 122, 2528-2528.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Targeting Oncogenic Interleukin-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2535-2535.	1.4	0
218	The Safety and Adherence To Prophylactic Anticoagulation During Induction Chemotherapy In Adults With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 3867-3867.	1.4	0
219	A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. Blood, 2015, 126, 2553-2553.	1.4	0
220	Identification of CKMT1B As a New Target in EVI1-Positive AML. Blood, 2015, 126, 3674-3674.	1.4	0
221	Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone. Blood, 2015, 126, 2126-2126.	1.4	0
222	Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. Blood, 2015, 126, 5142-5142.	1.4	0
223	A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2015, 126, 2550-2550.	1.4	0
224	Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML. Blood, 2015, 126, 870-870.	1.4	0
225	Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML. Blood, 2015, 126, 326-326.	1.4	0
226	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. Blood, 2015, 126, 1304-1304.	1.4	0
227	Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3310-3310.	1.4	0
228	A Distributed International Patient Data Registry for Hairy Cell Leukemia. Blood, 2016, 128, 5986-5986.	1.4	0
229	Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML). Blood, 2018, 132, 3895-3895.	1.4	0
230	Experience with IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2021, 138, 1284-1284.	1.4	0
231	Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax. Blood, 2021, 138, 4126-4126.	1.4	0
232	Switching drugs midstream for patients with chronic myeloid leukemia. Clinical Advances in Hematology and Oncology, 2014, 12, 466-8.	0.3	0